Pulmonary
Partner With Us
Advertisement
Conexiant chevron_right Pulmonary chevron_right Bedaquiline Resistance Worsens TB Treatment Outcomes
From the Journals

Resistance to Bedaquiline Impacts TB Survival

A cohort study found that patients with bedaquiline-resistant tuberculosis had delayed microbiologic recovery, higher rates of treatment failure, and reduced tuberculosis-free survival at 18 months compared with those with bedaquiline-susceptible disease.

Conexiant
Full Article Summary Notecard
  1. Bedquiline-resistant TB shows prolonged recovery times compared to drug-susceptible TB.
  2. 52% achieved TB-free survival at 18 months.
  3. Median treatment duration was 17.7 months. 
  4. 21% developed linezolid resistance over time.
  5. Urgent need for rapid resistance testing and new therapeutic options.

Source: The Lancet Infectious Diseases

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.